8-K: Codexis Appoints Cynthia Collins to Board of Directors, Enhances Compensation Committee

Codexis, Inc. appoints Cynthia Collins to its Board of Directors and Compensation Committee, effective immediately.

Summary

• Codexis, Inc. has appointed Cynthia Collins to its Board of Directors as a Class II director, effective March 28, 2025.
• Ms. Collins will serve an initial term expiring at the 2027 annual meeting of stockholders.
• The Board has determined that Ms. Collins is independent as defined by Nasdaq Listing Rule 5605.
• Ms. Collins has also been appointed to the Compensation Committee of the Board.
• She currently serves as Executive Chair and Interim CEO of Nutcracker Therapeutics, Inc.
• Ms. Collins has previously served as CEO of Editas Medicine, Human Longevity Inc., and GenVec, Inc.
• She also holds board positions at several healthcare companies, including MaxCyte, Inc., Alanis Therapeutics Inc., Certara, Inc., DermTech, Inc., Draper Laboratory, and Panavance Therapeutics Inc.
• Ms. Collins will receive an annual cash retainer of $50,000 for her board service and an additional $20,000 for her service on the Compensation Committee.
• She was granted restricted stock units (RSUs) equal to $200,000 divided by the closing trading price of Codexis' common stock on March 28, 2025, which was $2.81 per share.
• These RSUs vest in equal installments over three years, contingent on her continued service.
• On each annual meeting date, Ms. Collins will automatically be granted restricted stock equal to $100,000 divided by the per share closing trading price on that date.
• Codexis expects to enter into its standard indemnification agreement with Ms. Collins.

Sentiment

Score: 7

Explanation: The appointment of an experienced director is generally viewed positively, suggesting a stable and competent leadership structure. The compensation details are standard and don't raise any red flags.

Positives

• The appointment of Cynthia Collins, an experienced executive with a strong background in healthcare and biotechnology, could bring valuable expertise and insights to the Codexis Board.
• Her experience as CEO of Editas Medicine, Human Longevity Inc., and GenVec, Inc., as well as her current board positions in several healthcare companies, suggests she has a deep understanding of the industry.
• Her appointment to the Compensation Committee could enhance the committee's effectiveness in designing and overseeing executive compensation programs.

Future Outlook

The company expects to enter into its standard indemnification agreement with Ms. Collins.

Industry Context

The appointment of an experienced executive like Cynthia Collins, with a background in gene therapy and biotechnology, aligns with the industry's focus on innovation and growth in these areas. Her experience in both private and public companies, including Editas Medicine, a gene editing company, is relevant to Codexis's business.

Comparison to Industry Standards

• Director compensation packages, including cash retainers and equity grants, are common practice in publicly traded companies to attract and retain qualified board members.
• The annual cash retainer of $50,000 plus $20,000 for committee service is within the typical range for companies of Codexis' size and industry.
• Equity grants, such as the RSU grants to Ms. Collins, are also standard practice to align directors' interests with those of shareholders.
• Comparing Codexis' director compensation policy to companies like Amyris, Intellia Therapeutics, or CRISPR Therapeutics would provide a more detailed benchmark.

Management Changes

Stakeholder Impact

• Shareholders may view the appointment of an experienced director positively, potentially increasing confidence in the company's governance and strategic direction.
• Employees may benefit from Ms. Collins' expertise and leadership, potentially leading to improved company performance and opportunities.
• The appointment could strengthen the company's relationships with customers and partners, as Ms. Collins' network and experience could facilitate new collaborations and business opportunities.

Key Dates

Keywords

Board of Directors, Cynthia Collins, Compensation Committee, Appointment, Codexis, Governance, Director, RSU